The relationship between osteoporosis drugs and kidney damage is unclear. In this study, we plan to reveal relationship between osteoporosis drugs and kidney damage.
- Study Type: Observational
- Study Design
- Time Perspective: Retrospective
- Study Primary Completion Date: December 2018
Chronic kidney disease (CKD)- mineral and bone disorder (CKD-MBD) is one of the topic in osteoporosis treatment. As many osteoporotic patients are older, many patients are under the deterioration of the renal function. In addition, several drugs might have the potential for kidney damage. But the relationship between osteoporosis drugs and kidney damage is unclear.
The main objective of this study is to reveal relationship between osteoporosis drugs and kidney damage.
- Drug: Bis, SERM Teriparatide, Denosumab
- Osteoporotic drugs are assigned according to the disease severity, gender, age and so on.
Arms, Groups and Cohorts
- Selective estrogen receptor modulator
Clinical Trial Outcome Measures
- Longitudinal renal function changes by osteoporotic treatment
- Time Frame: Up to 120 months
Participating in This Clinical Trial
- Osteoporosis patients
- eGFR < 15
Gender Eligibility: All
Minimum Age: 45 Years
Maximum Age: N/A
Are Healthy Volunteers Accepted: No
- Lead Sponsor
- Toshihiko Kono
- Provider of Information About this Clinical Study
- Sponsor-Investigator: Toshihiko Kono, Head of Hospital – Tomidahama Hospital
- Overall Official(s)
- Rui Niimi, MD, Principal Investigator, Tomidahama Hospital
- Overall Contact(s)
- Rui Niimi, MD, (81)-59-365-0023, email@example.com
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.